Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products under the Changlong and...
Jilin Province Huinan Changlong Bio-Pharmacy FY26 H1 profit attributable to shareholders rises 19.25% to RMB 122.84 million; revenue slips 0.87% to RMB 435.05 million
Pre-market hot trades in US stocks: Gaxos.ai pre-market down 12.70%; Reddit pre-market up 12.46%
Offshore Capital Reassesses Hong Kong Periphery as Property Liquidations Contrast with Green Resilience
Huinan Changlong Bio-Pharmacy schedules board meeting to review interim results
Morning Trend | JILIN CHANGLONG's main force tests again, is a medium-term swing opportunity emerging?
JILIN CHANGLONG subscribed to RMB 50 million of China Industrial and Commercial Bank wealth management products